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2014 to December 2016)
Alexandre Blikstad Mauro1, Eder Gatti Fernandes2, Karina Takesaki Miyaji1, 
Benedito Antônio Arantes2, Maria Gomes Valente2, Helena Keico Sato2, Ana 
Marli C. Sartori 1 
ABSTRACT
In March 2014, the Quadrivalent human papilloma virus vaccine (4vHPV) was introduced 
in the female adolescents vaccination schedule of the National Immunization Program (PNI). A 
school-based vaccination program was implemented. We conducted a retrospective, descriptive 
study of the adverse events that took place after HPV vaccination, reported to the Adverse Events 
Following Immunization (AEFI) Information System in Sao Paulo State, from March 2014 
to December 2016. All reports that fit the definitions of the 2014 National Manual on AEFI 
surveillance were included. AEFI risk was estimated by dividing the number of reports by the 
number of vaccine doses administered in the period. In the three-year period, 3,390,376 HPV 
vaccine doses were administered and 465 AEFI reports were registered, with 1,378 signs and 
symptoms. The reporting rate was 13.72 per 100,000 vaccine doses administered. The reports 
peaked in the first year of the program. The most frequent AEFI was syncope, with 5.7 reports 
per 100,000 doses administered, followed by dizziness, malaise, headache and nausea. Overall, 
39 AEFI cases (8.4%) were classified as severe , with a reporting rate of 1.15 per 100,000 
vaccine doses administered. Most cases were classified as severe because of hospitalization. 
Among them, there were cases of Guillain-Barré Syndrome, deep vein thrombosis, seizures and 
miscarriage. All young women recovered without sequelae. We identified five clusters of AEFI 
reports in four cities; the larger AEFI cluster occurred in the city of Bertioga, in September 2014, 
involving 13 female adolescents. Our data are in accordance with those from other countries 
and corroborate the safety of HPV vaccines. 
KEYWORDS: Papillomavirus vaccines. Human papillomavirus recombinant vaccine 
Quadrivalent, genotypes 6, 11, 16, 18. Adverse effects Adverse Drug Reaction Reporting 
Systems. Immunization Stress Related Response. Vaccination. 
INTRODUCTION
Human papillomavirus (HPV) is the most common sexually transmitted infection 
and most people are infected shortly after the onset of sexual activity. There are 
more than 150 different HPV genotypes. Fifteen high-risk HPV genotypes can cause 
cervical cancer, the most common HPV-related disease. High-risk HPV may also 
cause cancer of the anus, vulva, vagina, penis and oropharynx. Other non-oncogenic 
types of HPV may cause genital warts. 
Three HPV vaccines containing the recombinant viral structural protein (L1) are 
currently available: a bivalent vaccine (2vHPV) composed of HPV genotypes 16 and 
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18, responsible for 70% of cervical cancers; a tetravalent 
vaccine (4vHPV), which, in addition to HPV 16 and 18, 
contains types 6 and 11, responsible for 90% of genital 
warts; and a nine-valent vaccine (9vHPV), composed of 
HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58, expanding 
the coverage of the high risk HPV genotypes to prevent 
more than 90% of cervical cancers1. 
The introduction of HPV vaccine in the immunization 
schedule of adolescents has reduced the prevalence of 
vaccine-covered HPV genotypes in countries that achieved 
moderate to high vaccination coverage, with evidence of 
herd protection2,3, and without any evidence of genotype 
replacement to date3. The 4vHPV vaccine effectiveness in 
preventing cervical intraepithelial neoplasia grade 2 (CIN-2) 
or worse, including CIN-3, carcinoma in situ, adenocarcinoma 
in situ, and cervical cancer, in routine immunization of young 
women has already been demonstrated4.
Phase 3 clinical trials and phase 4 observational studies 
indicated that HPV vaccines are safe. Most adverse events 
following immunization (AEFI) were mild and moderate, 
mainly injection site reactions such as pain and swelling. 
The most frequent systemic AEFI were fever, headache, 
fatigue and dizziness5.
In March 2014, the 4vHPV vaccine was introduced in 
the immunization schedule of adolescents, being part of 
the Brazilian National Immunization Program (PNI) as a 
two-dose schedule, with a 6-month interval between doses6. 
It has been initially introduced for female adolescents 
aged 11-13 years; in the following year, it was expanded 
for females aged 9-13 years old. In 2017, a gender-neutral 
program was adopted so that the vaccine was recommended 
for males aged 12-13 years old7. In 2019, the vaccine has 
been recommended for females aged 9-15 years old and 
males 11-14 years old. 
In 2014, a school-based program was implemented 
in the country for the first time, involving both public 
and private schools and two annual campaigns (March 
and September). The vaccine was also available in public 
primary healthcare units throughout the year. The Brazilian 
Unified Health System (SUS) also provides the 4vHPV 
vaccine in a three-dose schedule for males and females 
living with HIV, transplant recipients and patients with 
cancer, up to 26 years of age7. In the private health sector, 
the 2vHPV and 4vHPV vaccines are available for males 
and females up to 45 years old.
The school-based vaccination program enabled a 
high HPV vaccine coverage. The first campaign (March 
2014), involved a large mobilization of both, healthcare 
professionals as well as the general population, and was 
successful. The national mean vaccine coverage was 
94.4% and most States reached the PNI goal of 80% 
coverage; in Sao Paulo State, the coverage was 102%. In 
the second semester of 2014, the vaccine coverage dropped 
continuously until the end of that year, the national mean 
coverage of the second HPV vaccine dose was only 40.8% 
and, in Sao Paulo State, it was 44.6%8. The causes of this 
drop in HPV vaccine coverage are not completely clear, but 
the widespread disclosure in the traditional and social media 
of a cluster of adverse events following 4vHPV vaccination 
in a school in the city of Bertioga, a coastal city in Sao Paulo 
State, in September 2014, may have had a role9. 
This study aimed to describe the adverse events 
following the HPV vaccination reported to the Sao Paulo 
State Surveillance System, in the first three years after 
the introduction of the 4vHPV vaccine in the routine 
immunization schedule of adolescents (March 2014 to 
December 2016).
METHODS
Study design and source of information
We conducted a retrospective, descriptive study of 
the adverse events after the HPV vaccination, reported 
to the Adverse Events Following Immunization (AEFI) 
Surveillance System in Sao Paulo State, from March 2014 
to December 2016. 
Sao Paulo State is located in the Southeast of Brazil and 
has 645 municipalities that account for a third of the gross 
domestic product and a fifth of the Brazilian population.
Surveillance of adverse events following immunization 
in Brazil 
The National AEFI Surveillance System was 
implemented in Brazil, in 1998. It is a passive surveillance 
system composed of cases reported by health professionals 
from both, public and private health sectors. Since 2005, 
AEFI reporting has been mandatory nationwide. Reporting 
forms are nationally standardized and collected data 
enter into an online Information System managed by the 
Ministry of Health (Sistema de Informações de Eventos 
Adversos Pós Vacinação, SI-EAPV). A national manual 
on AEFI surveillance standardizes all the definitions and 
procedures, in accordance with the Brighton Collaborative 
Group, providing definitions of adverse events severity and 
causality that are in line with international guidelines10. 
We analyzed all reports of adverse events following HPV 
vaccination that fit in the definitions of the 2014 National 
Manual on AEFI surveillance10. An AEFI is defined as 
any untoward medical occurrence temporarily associated 
with vaccination, which does not necessarily have a causal 
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relationship with the vaccine. Adverse events are classified as 
severe if they resulted in hospitalization for more than 24 h 
or prolongation of a pre-existing hospitalization; significant 
dysfunction and/or persistent disability; congenital anomaly; 
risk of death or death. AEFIs are classified as non-severe if 
they involve other events that are not listed as severe10. 
For this study, data were extracted from the AEFI 
Surveillance System databases and from AEFI reporting 
forms sent to the Surveillance Center of the Sao Paulo 
State Department of Health (CVE/SES-SP). AEFI 
reports that were discarded by the Surveillance System, 
because patients had other diagnoses that justify the signs 
and symptoms and reports that did not have sufficient 
information to characterize the event were excluded. We 
collected the following information from the reported cases: 
demographic information, vaccination date, dose number, 
concomitant vaccines, signs and symptoms, provided 
healthcare, diagnosis and case severity. 
The number of HPV vaccines doses administered in 
Sao Paulo State was extracted from the Ministry of Health 
website (DATASUS) and from the Immunization Division 
of CVE/SES-SP database. We organized the collected data 
in a single database.
Statistical analysis
We estimated frequencies for categorical variables, 
means, medians and standard deviations for continuous 
variables. The risk of AEFI was estimated by dividing 
the number of reports by the number of vaccine doses 
administered in the studied period. We used the Microsoft 
Excel 2010 and the Epi-Info version 7.2.2.2.
Ethical considerations
The Research Ethics Committee of the Medical School 
of the University of Sao Paulo approved this study (Report 
Nº 214/16).
RESULTS
From March 1st, 2014 to December 31st, 2016, a total 
of 475 reports of adverse events following the HPV 
vaccine were retrieved from the AEFI Surveillance System 
database, of which 10 were excluded. Seven of the excluded 
reports presented other diagnoses that justified the signs 
and symptoms and the other three reports had insufficient 
information to be characterized as AEFI. We analyzed 465 
reports of adverse events following HPV vaccination and 
1,378 signs and symptoms. Overall, 3,390,376 HPV doses 
were administered in Sao Paulo State, in the same period, 
with an AEFI reporting rate of 13.71 per 100,000 HPV 
vaccine doses administered. 
A large number of AEFIs were reported in the first 
months after the introduction of the 4vHPV vaccine in 
the routine immunization schedule of adolescents, with 
337 reports in 2014 (209 and 128 reports in the first and 
second semester, respectively). The number of reports 
declined in the following years (Table 1), two reports, 
however, did not describe the date of vaccination nor the 
date of the AEFI. Taking into account the number of doses 
administered each year, the AE reporting rate varied from 
19 per 100,000 HPV doses administered, in 2014, to 6 per 
100,000 doses administered, in 2015, and 10 per 100,000 
doses administered, in 2016 (Table 1).
All the reported AEFIs occurred in young women; 
the mean age was 11.8 and the median age was 12 years 
(minimum, 9 and maximum, 29 years; only one woman 
was 29 years old, all the others were up to 15 years). Only 
23 (4.95%) of the 465 adolescents received concomitant 
vaccines alongside with HPV; the most frequent was yellow 
fever (14), followed by influenza (5), MMR (3), dT (2) and 
hepatitis B (1).
Syncope was the most frequently reported event (197 
events, noted in 42.5% of the AEFI reports, with a reporting 
rate of 5.7 per 100,000 HPV vaccine doses administered), 
followed by dizziness, malaise, headache and nausea. Pain 
Table 1 - Number of adverse events (AE) following HPV vaccination reports, classification and reporting rates (per 100,000 doses 
administered), by year of occurrence, in Sao Paulo State, Brazil, from March 1st, 2014 to December 31st, 2016.
Year
Number of HPV 
vaccine doses 
administered
Severe AE 
 reports (N=39)
Non-severe  AE  
reports (N=426)*
Total reports 
(N=465)*
Reporting rate  
per year
2014 1,697,700 19 318 337 19
2015 1,256,589 18 63 81 6
2016 436,087 2 43 45 10
Reporting rate per 
type of AE for the 
entire period
3,390,376 1.15 12.56 13.71
*Date of occurrence was not reported in two cases. 
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and/or erythema were the most commonly reported local 
adverse events (Table 2).
Most AEFI (64.73%, 301/465 reports) occurred after 
the first HPV vaccine dose, and in most reports (68.39%, 
318/465) the signs and symptoms started within the first 
hour after immunization. 
Overall, 39 cases (8.4%) were classified as severe AEFI, 
with a reporting rate of 1.15 per 100,000 vaccine doses 
administered; and 426 (91.6%) were non-severe with a 
reporting rate of 12.56 per 100,000 doses administered 
(Table 1). Among the 39 severe AEFI reported, we identified 
two cases of Guillain-Barré Syndrome (GBS), one case of 
upper-extremity deep vein thrombosis, one case of seizures 
with cerebral edema in a young women with history of 
epilepsy and one miscarriage. The remaining 34 cases were 
classified as severe because they resulted in hospitalization 
for more than 24 h. The following symptoms and signs 
were mentioned in these 34 reports: headache (17 reports), 
Table 2 - Number and reporting rates of adverse events following 4vHPV vaccination reported to the Adverse Events Following 
Immunization Surveillance System in the Sao Paulo State, Brazil, from March 1st, 2014 to December 31st, 2016.
AEFI signs and symptoms Number % of all AEFIs reported Reporting rate per 100,000  doses administered
Systemic
Syncope 197 14.3 5.8
Dizziness 186 13.5 5.5
Malaise 160 11.6 4.7
Headache 152 11.0 4.5
Nausea 125 9.1 3.7
Vomiting 66 4.8 1.9
Paresthesia 55 4.0 1.6
Fever 48 3.5 1.4
Drowsiness 47 3.4 1.4
Urticaria 37 2.7 1.1
Myalgia 33 2.4 1.0
Rash 33 2.4 1.0
Cyanosis of extremities 30 2.2 0.9
Seizures 25 1.8 0.7
Shortness of breath 15 1.1 0.4
Tremors 13 0.9 0.4
Irritability 8 0.6 0.2
Paralysis 8 0.6 0.2
Diarrhea 8 0.6 0.2
Arthralgia 6 0.4 0.2
Hypothermia 3 0.2 0.1
Parotiditis 2 0.1 0.1
Guillain Barré Syndrome 2 0.1 0.1
Cough 2 0.1 0.1
Deep vein thrombosis 1 0.1 0.03
Wheezing 1 0.1 0.03
Persistent crying 1 0.1 0.03
Miscarriage 1 0.1 0.03
Local
Pain and swelling 107 7.8 3.2
Nodule 6 0.4 0.2
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syncope (12), paresthesia (12), fever (11), dizziness (10), 
injection site pain and erythema (10), rash (7) and nausea 
(5). All young women recovered with no sequelae. 
The duration of the non-severe AEFI was ≤6 h in 
90% (383/426) of cases and >6 h in 4% (19/426). On the 
other hand, 46% (18/39) of the serious AEFI lasted ≥6 h. 
Considering all AEFI reports, the symptoms lasted less than 
one hour in 43.66% (203/465).
Regarding the vaccination setting, 30.97% (144) of 
the reports refer to young women vaccinated in schools, 
and 66.45% (309) to young women vaccinated in public 
primary healthcare units (12 reports did not describe the 
vaccination setting).
After grouping the AEFI reports by city of residence, 
we identified five AEFI clusters in four cities (Table 3). 
Unlike the occurrence in larger cities, where the number 
of reports was greater, distributed over time and involving 
people vaccinated in different settings, these clusters were 
registered in smaller municipalities and involved individuals 
vaccinated in the same health unit or school, on the same day. 
The larger AEFI cluster (13 cases) occurred in Bertioga, a 
coastal city with 56,000 inhabitants, in September 2014. All 
13 young women were vaccinated at the same school, on the 
same day. The first signs and symptoms were headache (13), 
dizziness (13), paresthesia (10) and syncope (8) and they 
initiated two hours after vaccination. The adolescents 
were evaluated in health services and three of them 
were hospitalized due to lower limbs weakness with gait 
disturbance. Their physical examination were normal and 
the complementary imaging exams (CT and/or MRI), the 
electroencephalogram and/or the electroneuromyography 
showed no abnormalities so that the hypothesis of organic 
disease was discarded. All young women had a complete 
resolution of the clinical manifestations within a week, 
without any specific treatment or sequelae. The medical 
investigation concluded that the events were probably 
“immunization stress related response (ISRR)”. There 
were other four AEFI clusters, identified in the cities of 
Valinhos, Pracinha and Cabreuva (Table 3), which did 
not involve hospitalization or severe AEFI. These young 
women were vaccinated at the same place, on the same 
day and presented similar, but milder symptoms than those 
observed in the Bertioga cases (headache, dizziness, nausea, 
and malaise). Four of these clusters occurred among those 
vaccinated in schools; only one occurred in a public basic 
health unit (Table 3). The municipal health surveillance 
team followed up and investigated these cases, which did 
not obtain significant media coverage.
DISCUSSION
In this study, we analyzed the adverse events following 
HPV vaccination reported to the surveillance system of Sao 
Paulo State, in the first three years after the introduction 
of the 4vHPV vaccine in routine immunization of female 
adolescents in Brazil. The overall AEFI reporting rate was 
13.71 per 100,000 vaccine doses administered. Systemic 
symptoms predominated and 39 serious adverse events were 
reported, with a severe AEFIs reporting rate of 1.15 per 
100,000 doses administered. The AEFI reporting rates 
peaked in the first year of the vaccination program, an 
expected behavior in passive surveillance systems11.
Direct comparison of our data with those from other 
countries is difficult due to differences in the surveillance 
systems and in the denominator used. While some studies 
use vaccine doses distributed12-16, our analysis was based 
Table 3 - Characteristics of the clusters of adverse events following HPV vaccination reported in Sao Paulo State, Brazil, from 
March 1st to December 31st, 2016.
Municipality Date of 
occurrence
Vaccination 
setting
Number of cases 
reported per cluster
Number of cases 
of severe 
adverse events 
Signs and symptoms 
Valinhos 03/21/2014 School 8 0
Local pain and swelling (6 cases), 
dizziness (6), headache (5), 
malaise (3)
Valinhos 03/24/2014 School 4 0 Dizziness (4 cases), headache (2), 
nausea (2)
Bertioga 09/03/2014 School 13 3
Headache (13 cases), dizziness 
(13), paresthesia (10) and 
syncope (8). Three girls presented 
lower limbs weakness with gait 
disturbance
Cabreuva 09/18/2014 School 5 0 Headache (3 cases), dizziness (3), 
urticaria (2), rash (2) 
Pracinha 09/25/2014 Health unit 9 0 Headache (6 cases), nausea (5)
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on doses administered. Our rates, however, are lower 
than those found in other studies. In the United States of 
America, from 2009 to 2015, more than 60 million HPV 
vaccine doses were distributed and the AEFI reporting rate 
to the Vaccine Adverse Event Reporting System (VAERS) 
was 327 cases per million doses distributed12. In Canada, 
the AEFI reporting rate was 37.4 cases per 100,000 doses 
distributed in Alberta, from 2006 to 201413, and 19.2 cases 
per 100,000 doses distributed in Ontario, from 2007 
to 201114. In Australia, from April 2007 to December 
2012, with more than 4.8 million HPV vaccine doses 
administered, the overall AEFI reporting rate was 34.8 cases 
per 100,000 doses administered and the rate of severe 
adverse events was 2.5 per 100,000 doses administered15. 
The reporting rate peaked in 2007, the year of the vaccine 
introduction, and declined substantially in the following 
years15. In the United Kingdom, from September 2008 to 
July 1st, 2012, with over 6 million doses of 2vHPV vaccine 
administered since licensure, the AEFI reporting rate was 
100/100,000 doses administered16. 
Syncope, which was the most frequently reported AEFI 
in our study, with a reporting rate of 5.7/100,000 doses 
administered, was also observed after HPV vaccination in 
other countries. In the USA, from 2009 to 2015, syncope 
reporting rate was 4.7/100,000 doses distributed12, and in 
Australia, from 2007 to 2012, it was 3.84/100,000 doses 
administered15. Syncope is not associated with the vaccine 
antigen itself, but rather with the vaccination process, 
and has also been observed after the administration of 
other vaccines, as well as after blood collection and the 
administration of parenteral drugs, especially among 
adolescents and young adults17,18. For that reason, it 
is recommended that adolescents remain seated in the 
vaccination setting for at least 15 minutes after HPV 
vaccine17. An analysis of USA VAERS data over a 10-year 
period (2007-2017) using disproportionality analysis, found 
that syncope and dizziness were associated with HPV 
vaccines19 in a statistically significant way.
In our study, most of the severe AEFI were considered 
because they had caused hospitalization. These AEFI were 
headache, syncope and paresthesia, and hospitalization was 
probably a measure to investigate them. However, among 
the severe AEFI, we identified cases of Guillain-Barré 
Syndrome (GBS), upper-extremity deep vein thrombosis, 
seizures and a miscarriage temporally associated with the 
HPV vaccine, all of which have already been reported 
by others12,15,16. Population-based studies found no 
evidence of an increased risk of these events following 
HPV vaccination5. In the USA, from 2006 to 2015, with 
more than 2.5 million HPV vaccine doses administered, 
an analysis of the Vaccine Safety Datalink (VSD) found a 
rate of 0.36 cases of GBS per million doses administered20. 
In Australia, the reporting rate of GBS following HPV 
vaccination was 0.04/100,000 administered doses15, which 
can be compared to our reporting rate of 0.1/100,000 doses 
administered. Another study in the USA that analyzed VSD 
data from 2008 to 2011, found no statistically significant 
increased risk of venous thromboembolism associated 
with HPV vaccine after analyzing 1.24 million doses 
administered21. 
The data analysis disclosed five AEFI clusters with 
4 to 13 cases, one of which had been widely reported in 
social and traditional media. Clusters of immunization 
stress related response (ISRR) have been observed in 
high, middle and low-income countries, with different 
vaccines implicated (tetanus-diphtheria, hepatitis B, 
influenza H1N1pdm09 and HPV)18. Clusters usually occur 
after the introduction of a new vaccine or modifications 
in the immunization schedule, and affect both, men and 
women, equally, especially in school-based programs18. All 
reports describe very similar symptoms, such as dizziness, 
headache and syncope18. Fear of injection is usual in older 
children and adolescents and may be exacerbated in some 
vaccination situations, when children who are waiting to be 
vaccinated may observe other children presenting ISRR18. 
Careless or sensationalist disclosure of AEFI cases in 
the media may undermine vaccination programs. A cross-
sectional study carried out in Vietnam demonstrated that the 
media has a major impact on the individuals consent to be 
vaccinated or to have their children vaccinated, 68.2% of 
the interviewees felt hesitant about vaccines after hearing 
on AEFIs on the media22. The hesitation following negative 
news in the media may undermine or even discontinue a 
country’s vaccination program, as occurred in Colombia23,24 
and Japan25,26.
In response to the repercussion of the Bertioga AEFI 
cluster in the social and traditional media, the managers of 
both the National and Sao Paulo State Health Department 
Immunization Program published technical reports 
reaffirming the 4vHPV vaccine safety9,27. The way public 
managers responsible for vaccination programs respond 
to uncertainty about vaccine safety may also affect the 
program. A rapid response to the community that includes 
medical aid, investigation of the AEFI, clarification of 
public concerns and transparency is essential to maintaining 
public confidence in the program.
This study has limitations. In addition to underreporting 
(particularly in case of mild AEFI), passive surveillance 
data are also more vulnerable to bias and confusion than 
clinical trials data11. During this study period, the National 
AEFI Information System was in process of transitioning 
to an online reporting system. At the time the old system 
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was being disabled, the AEFI reports associated with HPV 
vaccine were included in a parallel bank to ensure their 
registers, but some reports might have been lost. Data 
quality was also an issue. Some of the reports in this study 
were incomplete and difficult to interpret. Moreover, it is 
difficult to determine a causal relationship between an AEFI 
and the vaccine, because a correct causality assessment 
depends on careful analysis of quality and consistency of 
the data and the biological plausibility of the association. 
However, rare AEFI are detected only with the use of 
vaccines in routine immunization programs, which makes 
pharmacovigilance essential to ensure vaccines safety.
CONCLUSIONS
Our review of the first three years of HPV vaccination 
in Sao Paulo State demonstrated AEFI reporting rates 
consistent with those found in other countries. There were 
no deaths or permanent sequelae. We identified some AEFI 
clusters, especially in school-based vaccination programs. 
Our results are in accordance with data from other countries 
and ratify the safety of HPV vaccines.
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